

STIC-ILL

T1.55

mic

From: Kwon, Brian-Yong  
Sent: Thursday, September 12, 2002 7:03 PM  
To: STIC-ILL

scientific american, volume 275, no 1, july 1996, pages ~~38-43~~, "Sunlight and skin cancer", David J. Leffell and Douglas E. Brash

S2-59

Brian-Yong S. Kwon  
Patent Examiner, Pharm-D.  
CM1-2BO3, AU 1614  
(Tel)703-308-5377

# Sunlight and Skin Cancer


*Although most skin cancers appear in older people, the damage often begins decades earlier, when the sun's rays mutate a key gene in a single cell*

by David J. Leffell and Douglas E. Brash

In 1775 the British physician Percivall Pott reported a curious prevalence of ragged sores on the scrotums of many chimney sweeps in London. Other doctors might have concluded that the men were afflicted with a venereal disease that was then rampant throughout the city. But Pott was more astute. He realized they were in fact suffering from a type of skin cancer. Pott's discovery was a medical milestone. By observing that men continually exposed to coal tar were "peculiarly liable" to this form of cancer, he documented for the first time that cancer could be caused by an external agent rather than by internal factors.

More recently, investigators have identified another link between the environment and skin cancer, but this time the agent is much more ubiquitous. It is nothing less than light from the sun. The painstaking efforts of dozens of researchers have revealed a great deal about how solar rays contribute to the development of an astonishingly high number of skin cancers every year.

In the U.S. alone, about a million new cases occur annually, rivaling the incidence of all other types of cancer combined. Skin cancer typically takes one of three forms corresponding to the three major types of skin cells: basal cells, squamous cells and melanocytes. Cancer of melanocytes, called malignant melanoma, is the most lethal variety—and perhaps the most mysterious to researchers attempting to understand how these tumors are triggered. Fortunately, it is also the least common. In the U.S. there will be about 38,000 new cases of melanoma this year and approximately



**YOUNG BATHERS**, such as these Australian children, may predispose themselves to skin cancer as they play. Yet only one youngster here is taking precautions.

7,000 deaths from the disease. The two other forms, together called nonmelanoma skin cancer, account for the balance of the cases but kill a much smaller percentage of the affected population. A few thousand people are expected to die in the U.S. during 1996 from non-melanoma (almost exclusively squamous cell) skin cancer.

If caught early, most cases of nonmelanoma skin cancer are easily treated in a doctor's office under local anesthesia. Such cancers can be cured by a variety of simple techniques, including scraping, burning, freezing or surgically excising the malignant tissue. Even melanoma, if diagnosed when the tumor is still less than one millimeter thick, can usually be cured by simple excision. But because skin cancer plagues members of all age groups, and because it can become disfiguring and deadly if left untreated, medical researchers have mounted an immense scientific effort over the years

to unravel the mechanisms that cause this disease. Curiously, an accident of history contributed much to that quest.

## An Accidental Experiment

At the time Pott was studying scrotal cancer, Georgian England had a legal system that inflicted severe punishments for petty crimes: forgery or thievery often resulted in a death sentence. But a backlash against the harshness of execution for such misdemeanors soon led to milder sentences—and thus to the overcrowding of jails. To unburden the country's prisons, the House of Commons voted to banish criminals to remote locales beginning in the 1780s.

The destination of choice was a little known shore bordering the South Pacific Ocean. Within a few decades, the east coast of Australia was populated with British and Irish men and women. Those early colonists often shared the Celtic features of fair skin and light hair, and today their descendants predominate on that southern continent.


**HUMAN SKIN** includes three major cell types, all of which are susceptible to sunlight-induced cancer. Near the base of the epidermis lie round, basal cells. Closer to the surface are flattened, squamous cells. Melanocytes (cells that produce the protective pigment melanin) are interspersed in the basal layer and have numerous extensions that reach outward. Solar rays, which can penetrate well below the surface of the skin, damage segments of a cell's DNA that are particularly vulnerable to ultraviolet light. Damage to a gene called *p53* appears crucial to basal cell and squamous cell skin cancers.

SQUAMOUS  
CELL

# The Harder You Go, The

## Seville STS

With The Northstar System.



**The power behind  
the fluid grace.**

300-HP, 32-Valve Northstar V8

0-60 mph: 7.1 Seconds

**The technique that  
yields world-class  
performance.**

Full-Range Traction Control

Magnasteer<sup>TM</sup> Variable-Assist  
Steering

Continuously Variable  
Road-Sensing Suspension



**True champions  
come through over  
the long term.**

100,000 Miles Between  
Scheduled Tune-Ups

Up to 50 Miles Without a  
Drop of Coolant

Janet Evans  
Four-Time Olympic Medalist



36 USC 380

Official Sponsor of the  
1996 U.S. Olympic Team




Atlanta 1996  
TM, © 1992 ACOG

Official Sponsor of the  
1996 Olympic Games

For more information  
call 1-800-333-4CAD  
or on the Internet type  
<http://www.cadillac.com>.


# Endorphins Kick In.



SEVILLE STS

CADILLAC  
V-16

## How Sunlight Can Cause a Permanent Mutation



ULTRAVIOLET LIGHT can break chemical bonds in adjacent pyrimidine bases, often at a point on the DNA strand where two cytosines (C) occur. New bonds then form (red), linking the disrupted bases together in a so-called pyrimidine dimer.

REPLICATION requires that a cell separate the paired DNA strands (green and blue), each of which is used as a template to construct a new strand (purple)—by mating guanine (G) with cytosine and adenine (A) with thymine (T). The strand unaffected by sunlight produces normal DNA (left), but the strand containing the pyrimidine dimer produces disturbed Cs with As instead of matching them properly with Gs.

CONTINUED REPLICATION repeats the error, mating the dimer once more with a pair of As (right). On the opposite strand (left), these As are matched with Ts, creating a genetic mutation. The dimer may eventually be eliminated by "excision repair," but the C-to-T mutation is permanent. When such a mutation falls within a cancer-related gene, the cell becomes prone to malignancy.

What began as an 18th-century attempt at penal reform ultimately culminated in a de facto large-scale experiment on the links between complexion, solar radiation and skin cancer. With their fair skin continually exposed to intense sun, whites in Australia now have the highest rate of all kinds of skin cancer of any people in the world. Their British relatives, who live under cloudy northern skies, are more fortunate. They have a relatively low risk of acquiring these malignancies—as do Australian Aborigines, who with much darker skin are rarely affected by sun-induced cancers of the skin.


Investigators recognized as early as 50 years ago that the Australian experience implicated strong sun and fair skin as important risk factors for skin cancer. But for decades scientists were unable to explain what the sun was actually doing to skin cells to make them become cancerous. Clarifying that mystery required more than an accidental experiment on a sun-drenched continent. It took years of study in research laboratories of molecular biologists around the world before the details of that process began to be uncovered.

When the two of us started to attack this problem in the late 1980s, two types of insults from the sun seemed equally suspect. In one category were mutations of specific genes within skin cells. A cell may reproduce excessively if a mutation either turns a normal gene into an overzealous growth promoter (an oncogene) or inactivates a gene that normally limits cell growth (a tumor suppressor gene). The other class of causes we considered at the outset included more widespread events—ones that would affect every sun-exposed cell. For example, the sun's radiation might suppress the skin's immune response (reducing its natural ability to eliminate tumor cells) or directly stimulate cell division. With such diverse explanations possible, we knew that isolating the causes of skin cancer would not be easy.

But we were guided by the knowledge that the damaging effects of sunlight can occur many years before tumors appear. Such delayed effects were most clearly demonstrated in studies undertaken by Anne Krickler, then at the University of Western Australia, Robin Marks of the

What began as an 18th-century attempt at penal reform ultimately culminated in a de facto large-scale experiment on the links between complexion, solar radiation and skin cancer. With their fair skin continually exposed to intense sun, whites in Australia now have the highest rate of all kinds of skin cancer of any people in the world. Their British relatives, who live under cloudy northern skies, are more fortunate. They have a relatively low risk of acquiring these malignancies—as do Australian Aborigines, who with much darker skin are rarely affected by sun-induced cancers of the skin.

### YOUTH



GROWTH OF A NONMELANOMA SKIN TUMOR is thought to involve sunlight altering the *p53* gene in a squamous or basal cell of the skin (a). The mutation that results (b) de-

stroys the ability of genetically injured cells to delay replication until they have repaired their DNA. The *p53* mutation also prevents such cells from killing themselves when damaged beyond



Anti-Cancer Council of Victoria and their colleagues. They noted that people who had emigrated from cloudy England to sunny Australia before the age of 18 acquired the higher Australian incidence of skin cancers, but if they moved when they were older, they retained the native risk.

These findings indicated that Australian skin cancer patients must have received a critically high dose of sunlight years before the appearance of tumors (which rarely occurred before middle age). Widespread events, such as immunosuppression, last for only a few days after the injurious radiation ceases. But genetic changes persist (being passed from one generation of cells to another). Looking for genetic changes therefore seemed a more promising avenue for our research. So we began a hunt for sunlight-induced mutations that could occur early in life and set the stage for the development of skin cancer much later on.

### A Signature Mutation

That search was daunting. The DNA in a human cell contains as many as 100,000 genes, and each gene typically includes thousands of nucleotides (the building blocks of DNA)—only some of which would be likely to bear traces of sun-induced damage. And even if we managed to identify mutations in skin cancer samples, how could we be sure that sunlight had caused them? Fortunately, other investigators had given us a useful clue by finding that ultraviolet B radiation—long suspected to be the carcinogenic factor in sunlight—had a characteristic signature.

After studying everything from viruses to human cells, groups of researchers from Switzerland, France, Canada and the U.S. had shown that ultraviolet light causes mutations at points in a DNA strand containing specific nucleotide bases. Bases are the variable parts of nucleotides and go by the names adenine (A), guanine (G), cytosine (C) and thymine (T). Ultraviolet light creates mutations where a so-called pyrimidine base—cytosine or thymine—lies adjacent to another pyrimidine. About two thirds of these mutations are C-to-T substitutions, and about 10 percent of these changes occur at two adjacent Cs, with both bases changing to Ts. These features of the mutations created by ultraviolet light constitute a fingerprint of sorts, because they are made by no other agents.


We thus had a good idea of the kinds of distinctive mutations that should result from exposure to sunlight. But we needed to pinpoint which of the vast number of human genes mutated to produce a carcinogenic effect. Our best guess was that the solution lay with the handful of human genes already known to be involved in cancer.

Of the recognized oncogenes and tumor suppressor genes, we chose to examine a tumor suppressor gene called *p53*, which is now known to be mutated in more than half of all people's cancers. At the time, we suspected that *p53* might be involved in many cases of skin cancer because of an intriguing connection between nonmelanoma skin cancer and a rare affliction (epidermodysplasia verruciformis) that causes wartlike growths to appear on the skin.

Previous research had revealed that


such growths contain DNA from the human papillomavirus and that when these growths are located on sun-exposed skin, they can progress to basal cell or squamous cell cancer. Peter M. Howley and his colleagues at the National Cancer Institute had further shown that one of the proteins made by the papillomavirus inactivates the *p53* protein. (Genes give rise to proteins, and the *p53* protein, as might be expected, is the product of the *p53* gene.) So all indications were that *p53* might play a special role in nonmelanoma skin cancer. But we needed solid confirmation.

To find that proof, we studied squamous cell carcinomas, tumors unquestionably linked to sunlight (they occur on the face and hands, especially among whites living in the tropics). In collaboration with Jan Pontén of Uppsala University Hospital in Sweden, we discovered that more than 90 percent of the squamous cell carcinomas from a set of samples collected in the U.S. had a mutation somewhere in the *p53* tumor suppressor gene. These mutations occurred at sites with adjacent pyrimidine bases, and they had the distinctive C-to-T pattern associated with ultraviolet exposure. Our research group, along with several others, later pinpointed sunlight-related *p53* mutations in basal cell carcinomas as well. (Melanoma does not appear to be associated with alterations to *p53*. Researchers are still studying cancerous melanocytes for genes affected by sunlight.) After examining samples in our laboratory, Annemarie Ziegler found that precancerous skin also contains mutations of *p53*, indicating that the genetic changes occur long before



repair. If sunlight later burns unaltered cells (c), massively damaged cells will commit "cellular suicide" and be replaced by cells derived from healthy skin nearby (d). But if sunlight burns tissue

near a *p53*-mutated cell that cannot self-destruct (e), the mutated cell may replace the dying, sunburned cells with its own progeny (f), thereby promoting growth of a tumor.



**SKIN CANCER RISK** depends greatly on exposure to solar ultraviolet radiation. Satellite measurements of ozone and cloud cover allow atmospheric scientists to estimate the amount of DNA-damaging ultraviolet light that reaches Earth's surface (shown here as an average for July 1992). Light-skinned people

living in parts of the U.S. exposed to intense ultraviolet rays during the summer months are most prone to skin cancer, because they produce less of the melanin pigment that protects dark skin from ultraviolet damage. The bar graphs show incidence rates for nonmelanoma skin cancer in whites.

LABORATORY FOR ATMOSPHERES, NASA GODDARD SPACE FLIGHT CENTER; NATIONAL CANCER INSTITUTE; LAURIE GRACE

tumors appear. But were these mutations truly the cause of nonmelanoma skin cancer, or were they simply an irrelevant indicator of lifetime exposure to sunlight?

We could rule out this last possibility by the particular way the genetic code had been altered. The nucleotides in genes are arranged in well-defined codons—groups of three bases that specify different amino acids. The sequence of codons in a gene determines the sequence of amino acids that are strung together to construct a protein. But different codons can sometimes specify the same amino acid—as if the name of the amino acid could be spelled any of several ways. Typically the amino acid does not change when the first two bases of the codon are constant and only the third varies. Hence, if the *p53* mutations found in skin cancer were just a random effect of exposure to the sun, we would expect to find changes in the third position occurring as often as in the first or second. That is, there would be plenty of examples where the codon mutated (underwent a nucleotide base substitution) without altering its corresponding amino acid. Yet studies of this gene in skin cancers from around the globe had consistently revealed mutations that modified one or more amino acids in

the *p53* protein. These genetic changes to *p53*, then, were not just a side effect of ultraviolet exposure. They were in fact causing the skin cancers.

To better understand how the *p53* gene was affected in nonmelanoma skin cancer, we investigated whether certain segments of the *p53* gene were particularly prone to the mutation by sunlight of adjacent pyrimidine bases (that is, Cs or Ts). Biologists have found so-called mutation hot spots (places on a DNA strand where mutations tend to occur) whenever they expose living cells to carcinogens. After analyzing many tumors, we determined that the *p53* gene in nonmelanoma skin cancer contains about nine hot spots. In cancers unrelated to sunlight (such as colon or bladder cancer), five codons of *p53* are most often mutated, three of which are among the hot spots in skin cancers. At the two hot spots found only in the other cancers, the mutating C is flanked on either side by a G or A but never by a T or another C. Lacking a pair of pyrimidine bases, equivalent sites on the DNA of skin cells are protected from mutation by ultraviolet light.


Of the hundreds of places on the *p53* gene with adjacent pyrimidines, why do only a few sites act as hot spots when cells are exposed to sunlight? Several re-

searchers have recently helped answer that question by building on a discovery made more than three decades ago at Oak Ridge National Laboratory by Richard B. Setlow and William L. Carrier. Setlow and Carrier determined that cells can reverse ultraviolet damage to their DNA by an enzymatic process called excision repair. Cells essentially snip out disrupted bases and replace them with intact ones. Working in our lab in 1992, Subrahmanyam Kunala showed that cells repair damage particularly slowly at some pyrimidine pairs. Subsequently, Gerd P. Pfeifer and his colleagues at the City of Hope Beckman Research Institute in Duarte, Calif., found that cells repair the *p53* sites mutated in nonmelanoma skin cancer more sluggishly than they do many other sites in the gene. Hence, it seems quite likely that the hot spots we found for skin cancer owe their existence to an inability of skin cells to mend these sites efficiently.

### Cellular Proofreading

Even after we had identified the relevant *p53* mutations, the story of carcinogenesis remained woefully incomplete. After all, genes do not get cancer—cells do. It was clear enough that the *p53* protein must operate in normal





## Subscribe to SCIENTIFIC AMERICAN

☒ **Yes! I want to subscribe for one year (12 issues) for just \$34.97. That's a savings of over 41% off the cover price.**

Name \_\_\_\_\_ (please print)  
Address \_\_\_\_\_ Apt. \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
This is a ☐ new ☐ renewal subscription  
☐ Payment enclosed ☐ Bill me Charge my ☐ MasterCard ☐ Visa ☐ American Express  
Card no. \_\_\_\_\_ Expires \_\_\_\_\_  
Signature \_\_\_\_\_  
Please allow 4-6 weeks for delivery of first issue. Rates outside the U.S.: \$47 in U.S. funds drawn on a U.S. bank. J6G320

## Subscribe to SCIENTIFIC AMERICAN

☒ **Yes! I want to subscribe for one year (12 issues) for just \$34.97. That's a savings of over 41% off the cover price.**

Name \_\_\_\_\_ (please print)  
Address \_\_\_\_\_ Apt. \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
This is a ☐ new ☐ renewal subscription  
☐ Payment enclosed ☐ Bill me Charge my ☐ MasterCard ☐ Visa ☐ American Express  
Card no. \_\_\_\_\_ Expires \_\_\_\_\_  
Signature \_\_\_\_\_  
Please allow 4-6 weeks for delivery of first issue. Rates outside the U.S.: \$47 in U.S. funds drawn on a U.S. bank. J6G320

## Give the gift of SCIENTIFIC AMERICAN

☒ **Please send a one year (12 issues) gift subscription for just \$34.97. That's a savings of over 41% off the cover price.**

To: Name \_\_\_\_\_ (please print)  
Address \_\_\_\_\_ Apt. \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
From: Name \_\_\_\_\_  
Address \_\_\_\_\_ Apt. \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
☐ Payment enclosed ☐ Enter a subscription in my name, too  
☐ Bill me Charge my ☐ MasterCard ☐ Visa ☐ American Express  
Card no. \_\_\_\_\_ Expires \_\_\_\_\_  
Signature \_\_\_\_\_  
Please allow 4-6 weeks for delivery of first issue. Rates outside the U.S.: \$47 in U.S. funds drawn on a U.S. bank. T6G31

Envision the  
faces of  
**SCIENTIFIC  
AMERICAN**  
See them 12  
times a year  
for just \$34.97  
and save  
over 41% off  
the cover  
price.





NO POSTAGE  
NECESSARY  
IF MAILED  
IN THE  
UNITED STATES


**BUSINESS REPLY MAIL**

FIRST-CLASS MAIL PERMIT NO. 139 HARLAN, IA

POSTAGE WILL BE PAID BY ADDRESSEE

**SCIENTIFIC  
AMERICAN**

PO BOX 3186  
HARLAN, IA 51593-2377



NO POSTAGE  
NECESSARY  
IF MAILED  
IN THE  
UNITED STATES


**BUSINESS REPLY MAIL**

FIRST-CLASS MAIL PERMIT NO. 139 HARLAN, IA

POSTAGE WILL BE PAID BY ADDRESSEE

**SCIENTIFIC  
AMERICAN**

PO BOX 3186  
HARLAN, IA 51593-2377



NO POSTAGE  
NECESSARY  
IF MAILED  
IN THE  
UNITED STATES

**BUSINESS REPLY MAIL**

FIRST-CLASS MAIL PERMIT NO. 139 HARLAN, IA

POSTAGE WILL BE PAID BY ADDRESSEE

**SCIENTIFIC  
AMERICAN**

PO BOX 3186  
HARLAN, IA 51593-2377



Use these  
postage-paid  
cards to  
subscribe to  
**SCIENTIFIC  
AMERICAN**  
today and  
save. (See other side.)

Visit our home page on the  
world wide web for informed  
coverage and authoritative  
analysis of developments in  
science and technology:  
<http://www.sciam.com/>

skin cells to prevent cancer, but how? One hint was available from Michael B. Kastan of Johns Hopkins Hospital. He found that cells subjected to x-rays stepped up production of the p53 protein, which in turn prevented the cells from dividing. Peter A. Hall and David P. Lane of the University of Dundee and Jonathan L. Rees of the University of Newcastle have shown a similar effect on the p53 protein in skin cells exposed to ultraviolet radiation. Cancer researchers speculate that the p53 protein normally stops a DNA-damaged cell from reproducing until it has had time to make repairs.

Moshe Oren and his colleagues at the Weizmann Institute of Science in Israel have proposed another function for the p53 protein as well: it can prevent cancer in situations where the DNA damage is too extensive to be repaired. They find that elevated levels of the p53 protein in a cell lead to apoptosis—programmed cell death. (Such cell death is a normal part of many biological processes, including embryonic development.) In this case, “suicide” of a sun-damaged cell would prevent it from becoming cancerous by permanently erasing its genetic mistakes. Such apoptosis could be called cellular proofreading. Because the skin sheds cells routinely, we surmised that skin cells often used p53 in this way. But even before we began to test our idea, some evidence was already available to support it.

Dermatologists have recognized for a long time that when skin is sunburned, some cells come to resemble apoptotic cells. By 1994 we could show that sunburned cells contained breaks in their DNA similar to those in other apoptotic cells. The sunburned cells thus ap-

peared to be in the process of committing cellular suicide, and we began immediately to wonder whether cells that had lost p53 could undergo such self-inflicted death.

At about the time we arrived at this investigative juncture, Tyler Jacks and his colleagues at the Massachusetts Institute of Technology had developed mice lacking the p53 gene. When Alan S. Jonason and Jeffrey A. Simon irradiated the skin of these so-called p53 knockout mice in our laboratory, they found far fewer sunburned, apoptotic cells than in normal mice exposed to the same ultraviolet radiation. Mice in which the p53 gene had been only partially inactivated had only a moderate tendency to undergo light-induced cell suicide. These results suggested that programmed cell death was important for preventing non-melanoma skin cancer and that loss of p53 could block this process.

### Double Punch from Sunlight

It is now possible to envision how the failure of cellular proofreading would lead to skin cancer. Normal skin exposed to sunlight will accumulate DNA damage caused by the ultraviolet B part of the solar spectrum. Cells unable to repair their DNA in a timely fashion die through apoptosis. But if the p53 gene in a cell has mutated during a previous episode of exposure to sunlight, that cell will resist such self-destruction—even if it has been badly injured.

The situation is actually much worse. A cell on the verge of becoming cancerous is surrounded by normal cells that undergo apoptosis when damaged. The dying cells thus must be leaving some space into which the p53-mutated cell

can grow. By inducing healthy cells to kill themselves off, sunlight favors the proliferation of p53-mutated cells. In effect, sunlight acts twice to cause cancer: once to mutate the p53 gene and then afterward to set up conditions for the unrestrained growth of the altered cell line. These two actions, mutation and tumor promotion, are the one-two blows of carcinogenesis. Although mutation and promotion are carried out by separate agents in other tumors, in skin cancer ultraviolet radiation appears to throw both punches.

There are undoubtedly other genes involved in the development of skin cancer as well as other effects of sunlight that researchers do not yet fully understand. For example, medical researchers know that Gorlin syndrome (a disease in which patients have multiple basal cell cancers) is caused by an inherited mutation in a different tumor suppressor gene. With further investigation, the various mechanisms of carcinogenesis will become even more clear, and scientists may find clever ways to interrupt the progression of normal skin cells to cancerous ones.

It is not beyond reason to hope that the detailed understanding researchers are gaining of nonmelanoma skin cancer will yield new kinds of therapies. Perhaps drugs that restore normal function to a mutated p53 protein will allow doctors to offer their patients an effective remedy that does not involve surgery. Such a cure, perhaps administered as a simple skin cream that is absorbed by the affected cells, might be available within the next decade or two. If so, it will be of great benefit to countless aging members of the sun-loving baby-boom generation—a group to which we both admittedly belong. □

### The Authors

DAVID J. LEFFELL and DOUGLAS E. BRASH have worked together for nearly a decade to understand the role of the sun in causing skin cancer. Leffell, a professor of dermatology and surgery at the Yale School of Medicine, has brought to their research collaboration the experience gained in clinical practice. He earned his M.D. at McGill University in 1981 and trained at Cornell Medical School, Memorial Sloan-Kettering Cancer Center and the University of Michigan before taking a position on the faculty at Yale in 1988. Brash, too, is on the medical school faculty at Yale, and his credentials include a bachelor's degree in engineering physics from the University of Illinois. He shifted from engineering to the study of biophysics at Ohio State University, where he received his Ph.D. in 1979. Thereafter Brash pursued postdoctoral training in microbiology (at the Harvard School of Public Health) and pathology (at Harvard Medical School) until 1984. He spent the next five years at the National Cancer Institute before moving to Yale.

### Further Reading

A ROLE FOR SUNLIGHT IN SKIN CANCER: UV-INDUCED p53 MUTATIONS IN SQUAMOUS CELL CARCINOMA. D. E. Brash, J. A. Rudolph, J. A. Simon, A. Lin, G. J. McKenna, H. P. Baden, A. J. Halper and J. Pontén in *Proceedings of the National Academy of Sciences U.S.A.*, Vol. 88, No. 22, pages 10124–10128; November 15, 1991.

SUNBURN AND p53 IN THE ONSET OF SKIN CANCER. A. Ziegler, A. S. Jonason, D. J. Leffell, J. A. Simon, H. W. Sharma, J. Kimmelman, L. Remington, T. Jacks and D. E. Brash in *Nature*, Vol. 372, pages 773–776; December 22–29, 1994.

CANCER FREE: THE COMPREHENSIVE CANCER PREVENTION PROGRAM. Sidney J. Winawer and Moshe Shike. Simon & Schuster, 1996.

SUNLIGHT, ULTRAVIOLET RADIATION AND THE SKIN. NIH Consensus Statement. Vol. 7, No. 8, pages 1–29; May 8–10, 1989. Available at <http://text.nlm.nih.gov/nih/cdc/www/74text.html>

This is Google's cache of <http://www.sciencedigest.org/0996TR.HTM>.

Google's cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. Click here for the [current page](#) without highlighting.

To link to or bookmark this page, use the following url:

<http://www.google.com/search?q=cache:t8x8q5DMkH8C:www.sciencedigest.org/0996TR.HTM+scientific+american+skin+cancer+p53&hl=en&ie>

*Google is not affiliated with the authors of this page nor responsible for its content.*

These search terms have been highlighted: **skin cancer p53**

These terms only appear in links pointing to this page: **scientific american**

## Genes And Cancer Risk

Inherited mutations in these genes confer a very high **cancer** risk. Red type indicates **cancer** most often associated with mutation in the listed gene.

GENE	TUMOR TYPE	GENE CLASS
BREAST <b>CANCER</b>	<i>BRCA1</i>	Breast, ovary
	<i>BRCA2</i>	Breast (both sexes)
	<b>p53</b>	Breast, sarcoma Tumor
COLON <b>CANCER</b>	<i>MSH2</i>	Colon, endometrium, other
	<i>MLH1</i>	Colon, endometrium, other
	<i>PMS1, 2</i>	Colon, other
	<i>APC</i>	Colon
MELANOMA	<i>MTS1 (CDKN2)</i>	<b>Skin</b> , pancreas
	<i>CDK4</i>	<b>Skin</b>
NEUROENDOCRINE <b>CANCER</b>	<i>NF-1</i>	Brain, other
	<i>NF-2</i>	Brain, other
	<i>RET</i>	Thyroid, other
KIDNEY <b>CANCER</b>	<i>WT1</i>	Wilms' tumor
	<i>VHL</i>	Kidney, other
RETINOBLASTOMA	<i>RB</i>	Retinoblastoma, sarcoma, other



This is Google's cache of [http://www.uke.uni-hamburg.de/Institutes/IZKN/ag\\_schmale1.de.html](http://www.uke.uni-hamburg.de/Institutes/IZKN/ag_schmale1.de.html).

Google's cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. Click here for the [current page](#) without highlighting.

To link to or bookmark this page, use the following url:

[http://www.google.com/search?q=cacne:63rDEzglGaUC:www.uke.uni-hamburg.de/Institutes/IZKN/ag\\_schmale1.de.html+cell+type+p63+gene&hl=en&le=UTF-8](http://www.google.com/search?q=cacne:63rDEzglGaUC:www.uke.uni-hamburg.de/Institutes/IZKN/ag_schmale1.de.html+cell+type+p63+gene&hl=en&le=UTF-8)

Google is not affiliated with the authors of this page nor responsible for its content.

These search terms have been highlighted: **cell type p63 gene**



Universitätsklinikum  
Hamburg-Eppendorf Fachbereich  
Medizin

Institut für  
Zellbiochemie  
und klinische  
Neurobiologie

Geschichte  
des Instituts

Aufgaben und  
Leistungen

Forschung

Lehre

Publikationen

Mitarbeiter-  
verzeichnis

Blankenese  
Konferenzen

Home

Mail

Suche

English

→ [Molecular cloning of taste receptors](#)

← [Signal transduction through neuropeptide receptors](#)

↑ [Zurück zur Übersicht "Forschung"](#)


## KET/p63: Splice variant analysis and regulation in keratinocytes

[Hartwig Schmale](#), Casimir Bamberger, Julia Bethge, Heidje Christiansen

The human **p63 gene** is a member of the p53 **gene** family comprising the three proteins p53, **p63** and p73. **p63** is abundantly expressed in proliferating basal cells of the epidermis. **p63** knock out-mice lack all squamous epithelia and they have severe limb truncations. In humans, mutations in **p63** are the cause for hand and feet anomalies in autosomal dominant disorders such as the EEC (ectrodactyl, ectodermal dysplasia, and facial clefts) syndrom.

In contrast to p53, the role of **p63** in tumorigenesis is not yet clear. We have identified one missense mutation in the DNA-binding domain of **p63** in 31 basal **cell** carcinomas studied. The low frequency of mutation suggests that the main biological role of **p63** is not in carcinogenesis.

While only one p53 form is known, multiple isoforms of **p63** and p73 have been described. The isoforms are generated by alternative splicing and by usage of different promoters. We have identified several tissue specific variations of exon 1 resulting in different amino-terminal ends. Transactivation properties of the splice variants inversely correlated with the length of the N-termini. Expression of a major KET variant appears to be a **cell-type** specific rather than a differentiation specific phenomenon.



The epidermis of **p63** knock out-mice undergoes an unusual process of non-regenerative differentiation possibly caused by the loss of the proliferative potential of epidermal keratinocytes. We have studied the expression pattern of **p63** in primary keratinocyte culture during autocrine terminal differentiation. The major isoform in proliferating keratinocytes is p63deltaN which lacks exons 2 and 3 coding for the transactivation domain. We showed a reduction of p63deltaN expression in keratinocyte culture when the cells began to differentiate. Treatment of primary human keratinocytes with all-trans retinoic acid prevents downregulation of **p63** during autocrine terminal differentiation. These data suggest that **p63** expression in human keratinocytes affected by all-trans retinoic acid might contribute to the fine tuned keratinocyte proliferation and differentiation equilibrium in the mammalian epidermis.

#### Collaborations

Dieter Pollet, Paul Gerson Unna-Skin Research Center, Beiersdorf AG, Hamburg  
Wolfgang Meyerhof, Deutsches Institut für Ernährungsforschung, Potsdam, Germany



[ [Home](#) ] [ [Mail](#) ] [ [Suche](#) ] [ [English](#) ]

*Letzte Änderungen: 4. Juli 2001, Arne Blichenberg*



This is Google's cache of <http://www.pol-us.net/PAPHome/Vol66/pap66719.html>.  
Google's cache is the snapshot that we took of the page as we crawled the web.  
The page may have changed since that time. Click here for the current page without highlighting.  
To link to or bookmark this page, use the following url:  
<http://www.google.com/search?q=cache:Rj1cyrkubvMC:www.pol-us.net/PAPHome/Vol66/pap66719.html+p53+gene+skin+cancer&hl=en&ie=UTF-8>  
*Google is not affiliated with the authors of this page nor responsible for its content.*

These search terms have been highlighted: **p53 gene skin cancer**

## UVB-induced Cyclobutane Pyrimidine Dimer Frequency Correlates with **Skin Cancer** Mutational Hotspots in **p53**

Régen Drouin and Jean-Philippe Therrien

Department of Medical Biology, Université Laval, Québec, Québec, Canada

\*To whom correspondence should be addressed at: Unit, de Recherche en Génétique Humaine et Moléculaire, Centre de Recherche, Pavillon Saint-François d'Assise, CHUQ, 10 rue de l'Espinay, Québec, Québec, G1L 3L5, Canada. Fax: 418-525-4481; e-mail: [regen.drouin@crsfa.ulaval.ca](mailto:regen.drouin@crsfa.ulaval.ca)

### ABSTRACT

Ultraviolet light has been identified as the major carcinogen in **skin cancer** and the **p53** tumor suppressor **gene** is a major target for UV-induced mutations. The mutations are probably caused by unrepaired UV-induced cyclobutane pyrimidine dimers (CPD) and possibly by the less frequent pyrimidine (6-4) pyrimidone photoproducts. While hot spots for **p53** mutations in human nonmelanoma **skin** tumors correspond quite well to slow spots for CPD repair in cultured cells irradiated with the model mutagen 254 nm UVC (which is not present in terrestrial sunlight), they do not all coincide with sequences that are initially frequently damaged by 254 nm UVC. Using LMPCR (ligation-mediated polymerase chain reaction), we show that environmentally relevant UVB light induces CPD at CC and PymC positions much more frequently than does UVC light, and that all eight **skin cancer** hot spots in **p53** are also hot spots for UVB-induced CPD. Our results show that methylation of dipyrimidine sites (PymCpG) is associated with an increase rate of CPD formation upon UVB irradiation. Consequently, DNA methylation may increase the mutagenic potential of UVB and explains that several **p53** mutation hot spots are found at PymCpG. The distribution patterns of CPD formation and the photofingerprint patterns found along exons 5 and 6 of **p53 gene** are suggestive of DNA folding into nucleosomes.

November 1997 Table of Contents

Photochemistry & Photobiology

Photobiology Online

This is Google's cache of [http://www.aspjournal.com/public/vol66/iss5/abstracts/abstractv66i5p719.html](http://www.aspjjournal.com/public/vol66/iss5/abstracts/abstractv66i5p719.html).

Google's cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. Click here for the [current page](#) without highlighting.

To link to or bookmark this page, use the following url:

[http://www.google.com/search?q=cache:SvaFBW4\\_YecC:www.aspjournal.com/public/vol66/iss5/abstracts/abstractv66i5p719.html+p53+gene+s](http://www.google.com/search?q=cache:SvaFBW4_YecC:www.aspjournal.com/public/vol66/iss5/abstracts/abstractv66i5p719.html+p53+gene+s)

*Google is not affiliated with the authors of this page nor responsible for its content.*

These search terms have been highlighted: **p53 gene skin cancer**

## Photochemistry and Photobiology

Published by the American Society for Photobiology

[Future Titles](#)

[Subscriptions](#)

[Editorial Board](#)

[Instructions to Authors](#)

[Archives](#)

[AB](#)

[SEARCH](#)

[BROWSE](#)

[authors](#)

[key categories](#)

[table of contents](#)

current issue:  Go

current issue: [authors](#) | [key categories](#) | [table of contents](#)

**Photochemistry and Photobiology**, Vol. 66, Iss. 5, P. 719

# UVB-induced Cyclobutane Pyrimidine Dimer Frequency Correlates with Skin Cancer Mutational Hotspots in *p53*

Régen Drouin\* and Jean-Philippe Therrien

Department of Medical Biology, Université Laval, Québec, Québec, Canada

## ABSTRACT

Ultraviolet light has been identified as the major carcinogen in **skin cancer** and the **p53** tumor suppressor **gene** is a major target for UV-induced mutations. The mutations are probably caused by unrepaired UV-induced cyclobutane pyrimidine dimers (CPD) and possibly by the less frequent pyrimidine (6-4) pyrimidone photoproducts. While hot spots for **p53** mutations in human nonmelanoma **skin** tumors correspond quite well to slow spots for CPD repair in cultured cells irradiated with the model mutagen 254 nm UVC (which is not present in terrestrial sunlight), they do not all coincide with sequences that are initially frequently damaged by 254 nm UVC. Using LMPCR (ligation-mediated polymerase chain reaction), we show that environmentally relevant UVB light induces CPD at CC and PyrmC positions much more frequently than does UVC light, and that all eight **skin cancer** hot spots in **p53** are also hot spots for UVB-induced CPD. Our results show that methylation of dipyrimidine sites (PyrmCpG) is associated with an increase rate of CPD formation upon UVB irradiation. Consequently, DNA methylation may increase the mutagenic potential of UVB and explains that several **p53** mutation hot spots are found at PyrmCpG. The distribution patterns of CPD formation and the photofingerprint patterns found along exons 5 and 6 of **p53 gene** are suggestive of DNA folding into nucleosomes.

**gene** are suggestive of DNA folding into nucleosomes.

\*To whom correspondence should be addressed at: Unit, de Recherche en Génétique Humaine et Moléculaire, Centre de Recherche, Pavillon Saint-François d'Assise, CHUQ, 10 rue de l'Espinay, Québec, Québec, G1L 3L5, Canada. Fax: 418-525-4481; e-mail: [regen.drouin@crsfa.ulaval.ca](mailto:regen.drouin@crsfa.ulaval.ca)

 P & P home

This is Google's cache of <http://p53.curie.fr/p53%20site%20version%202.0/p53%20in%20cancer/p53mutation>  
 Google's cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. Click here for the [current page](#) without highlighting.


To link to or bookmark this page, use the following url:

<http://www.google.com/search?q=cache:AyF2ONW1HJIC:p53.curie.fr/p53%2520site%2520version%25202.0/p53%2520in%2520cancer/p53mu>

*Google is not affiliated with the authors of this page nor responsible for its content.*

These search terms have been highlighted: **p53 gene skin cancer 1996**

## p53 IN SKIN CANCER



## FREQUENCY OF p53 MUTATIONS IN SKIN CANCER

Basal cell carcinoma is the most common form of **skin cancer**. The second most common type of **skin** malignancy is squamous cell carcinoma. Although these 2 types of **skin cancer** are the most common of all malignancies, they account for less than 0.1% of patient deaths due to **cancer**. Both of these types of **skin cancer** are more likely to occur in individuals of light complexion who have had significant exposure to sunlight, and both types of **skin** cancers are more common in the southern latitudes of the Northern hemisphere. The overall cure rate for both types of **skin cancer** is directly related to the stage of the disease and the type of treatment employed. However, since neither basal cell carcinoma nor squamous cell carcinoma of the **skin** are reportable diseases, precise 5-year cure rates are not known. Although basal cell carcinoma and squamous cell

carcinoma are by far the most frequent types of **skin** tumors, the **skin** can also be the site of a large variety of malignant neoplasms. These other types of malignant disease include malignant melanoma, cutaneous T-cell lymphomas (mycosis fungoides), Kaposi's sarcoma, extramammary Paget's disease, apocrine carcinoma of the **skin**, and metastatic malignancies from various primary sites

Basal cell carcinoma and squamous cell carcinoma are both of epithelial origin. They are usually diagnosed on the basis of routine histopathology. Squamous cell carcinoma is graded 1 to 4 based on the proportion of differentiating cells present, the degree of atypicality of tumor cells, and the depth of tumor penetration. Apocrine carcinomas, which are rare, are associated with an indolent course and usually arise in the axilla.

### **Basal cell carcinoma**

Basal cell carcinoma is at least 3 times more common than squamous cell carcinoma in nonimmunocompromised patients. It usually occurs on sun exposed areas of **skin**, and the nose is the most frequent site. Although there are many different clinical presentations for basal cell carcinoma, the most characteristic type is the asymptomatic nodular or nodular ulcerative lesion that is elevated from the surrounding **skin** and has a pearly quality and contains telangiectatic vessels. It is recognized that basal cell carcinoma has a tendency to be locally destructive. High-risk areas for tumor recurrence include the central face (periorbital region, eyelids, nasolabial fold, nose-cheek angle), postauricular region, pinna, ear canal, forehead, and scalp. A specific subtype of basal cell carcinoma is the morphea-form type. It typically appears as a scar-like, firm plaque and because of indistinct clinical tumor margins, it is difficult to treat adequately with traditional treatments.

### **Squamous cell carcinoma**

Squamous cell tumors also tend to occur on sun-exposed portions of the **skin** such as the ears, lower lip, and dorsa of the hand. However, squamous cell carcinomas that arise in areas of non-sun-exposed **skin** or that originate de novo on areas of sun-exposed **skin** are prognostically worse since they have a greater tendency to metastasize. Chronic sun damage, sites of prior burns, arsenic exposure, chronic cutaneous inflammation as seen in long standing **skin** ulcers, and sites of previous x-ray therapy are predisposed to the development of squamous cell carcinoma.

### **Actinic keratosis**

Actinic keratoses are potential precursors of squamous cell carcinoma. These typical red

scaly patches usually arise on areas of chronically sun-exposed skin, and are likely to be found on the face and dorsal aspects of the hand. Although the vast majority of actinic keratoses do not become squamous cell carcinomas, it is thought that as many as 5% of actinic keratoses will evolve into this locally invasive carcinoma. Due to this premalignant potential, the destruction of actinic keratoses is advocated.



UV radiation-induced mutations have been studied in various animal models. The majority of the mutations are found to be located at dipyrimidine sites (i.e. (T-T, C-C, C-T or T-C) and correspond to a C to T transition. More than 20% correspond to tandem mutations involving the two adjacent nucleotides of the dipyrimidine sites (C-C to T-T).



Several human genetic syndromes are associated with DNA repair deficiency. Among them, xeroderma pigmentosum (XP) is an autosomal, recessively inherited disease. Patients with XP show clinical and cellular hypersensitivity to UV radiation, resulting in a very high incidence of skin cancer. In these subjects, the median age of onset of skin cancer is 8 years, nearly 50 years younger than in the general population.

Brash et al. showed that, in skin spinocellular cancer, C → T mutations predominate in pyrimidine dimers. It is well known that ultraviolet radiation, an etiological agent of most skin cancers, acts directly on these dimers. A particular characteristic of the action of UV radiation is the change in the bases CC → TT, observed in Brash's series but also in other skin cancer series such as basocellular cancers (Rady et al. 1992). In patients with genetic DNA repair deficiencies, such as xeroderma pigmentosum (XP), the phenotype is much more marked. All mutations found in skin cancers are located on the pyrimidine dimers and 55 % are tandem mutations CC → TT (Dumaz et al. 1994). This type of mutation is only very rarely found in internal cancers (less than 1 %). In skin cancers from XP patients, more than 95 % of the mutations are located on the noncoding strand of the p53 gene, while in other skin tumors and in internal cancers, no special trends are observed. This result therefore suggests that there is preferential repair of the coding strand, which has been confirmed by Toranaletti and Pfeifer, who showed that the repair rate of pyrimidine dimers in the p53 gene is highly variable, with an especially low rate in the codons that are often mutated in skin cancer. Such p53 mutations seem to be very early events as they can be found both in precancerous lesions such as actinic keratosis (Ziegler et al. 1994) and in normal skin exposed to UV (Jonason et al. 1996). Recent work have demonstrated that human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes (Ponten et al. 1997; Ren et al. 1997; Ren et al. 1996; Ren et al. 1997; Ren et al. 1996).




These results taken together (predominance of CC → TT lesions on the non coding strand) were experimentally confirmed in animals carrying UV-induced tumors (Dumaz et al. 1997; Kress et al. 1992).





### Transition at Py-Py site in Skin cancer

BCC: basal cell carcinoma; SCC: squamous cell carcinoma of the skin; XP: xeroderma pigmentosum patients.



### Tandem mutation in Skin cancer

BCC: basal cell carcinoma; SCC: squamous cell carcinoma of the skin; XP: xeroderma pigmentosum patients.

### Key References

Ziegler A, Leffell DJ, Kunala S et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA. 1993; 90: 4216-20

Brash DE, Rudolph JA, Simon JA et al. A Role for sunlight in skin cancer - UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA. 1991; 88: 10124-8

Rady P, Scinicariello F, Wagner RF, and Tyring SK. p53 Mutations in Basal Cell Carcinomas. Cancer Res. 1992; 52: 3804-6

Sato M, Nishigori C, Zghal M, Yagi T, and Takebe H. Ultraviolet-Specific mutations in p53 gene in skin tumors in Xeroderma-Pigmentosum patients. Cancer Res. 1993; 53: 2944-6

Dumaz N, Drougard C, Sarasin A, and Dayagrosjean L. Specific UV-Induced mutation spectrum in the p53 gene of skin tumors from DNA-Repair-Deficient

Xeroderma-Pigmentosum patients. Proc Natl Acad Sci USA. 1993; 90: 10529-33

Dumaz N, Stary A, Soussi T, Dayagrosjean L, and Sarasin A. Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene? Mutat Res. 1994; 307: 375-86

Tornaletti S and Pfeifer GP. Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science. 1994; 263: 1436-8

Ziegler A, Jonason AS, Leffell DJ et al. Sunburn and p53 in the onset of skin cancer. Nature. 1994; 372: 773-6

Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, Leffell DJ, Tarone RE and Brash DE (1996) Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 93: 14025-14029.

Kress S, Sutter C, Strickland PT, Mukhtar H, Schweizer J, and Schwarz M. Carcinogen-Specific mutational pattern in the p53 gene in Ultraviolet-B Radiation-Induced squamous cell carcinomas of mouse skin. Cancer Res. 1992; 52: 6400-3

Ren ZP, Ahmadian A, Ponten F, Nister M, Berg C, Lundeberg J, Uhlen M and Ponten J (1997) Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. Am J Pathol 150: 1791-1803.

Ren ZP, Hedrum A, Ponten F, Nister M, Ahmadian A, Lundeberg J, Uhlen M and Ponten J (1996) Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene 12: 765-773.

Ren ZP, Ponten F, Nister M and Ponten J (1997) Reconstruction of the two-dimensional distribution of p53 positive staining patches in sun-exposed morphologically normal skin. Int J Oncol 11: 111-115.

Ren ZP, Ponten F, Nister M and Ponten J (1996) Two distinct p53 immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis. Int J Cancer 69: 174-179.

Dumaz N, vanKranen HJ, deVries A, Berg RJW, Wester PW, vanKreijl CF, Sarasin A, DayaGrosjean L and deGruijl FR (1997) The role of UV-B light in skin carcinogenesis

through the analysis of **p53** mutations in squamous cell carcinomas of hairless mice. Carcinogenesis 18: 897-904.

Ponten F, Berg C, Ahmadian A, Ren ZP, Nister M, Lundeberg J, Uhlen M and Ponten J (1997) Molecular pathology in basal cell **cancer** with **p53** as a genetic marker. Oncogene 15: 1059-1067.

---

### THE **p53** HOME PAGE

The APC Database---The **p53** Database --- **p53** Story---Anatomy of the **p53** gene --- Phylogeny of **p53**---**p53**: friends and foes---Other site on **p53**---Directory of **p53** scientists---The Lab---**p53**/p73 monoclonal antibodies---**p53** antibodies in human **cancer**---**p53** in lung **cancer**---**p53** in breast **cancer**---Mutation detection with DNA chips---Publications of the lab

---

This site was updated: December 2001

Improvements or Questions ? mail me : [thierry.Soussi@curie.fr](mailto:thierry.Soussi@curie.fr)

This is Google's cache of [http://www.visgen.com/Investors/Archived\\_Press\\_Releases/press3.shtml](http://www.visgen.com/Investors/Archived_Press_Releases/press3.shtml).

Google's cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. Click here for the [current page](#) without highlighting.

To link to or bookmark this page, use the following url:

[http://www.google.com/search?q=cache:mmA5-eZkzulC:www.visgen.com/Investors/Archived\\_Press\\_Releases/press3.shtml+p53+gene+skin+c](http://www.google.com/search?q=cache:mmA5-eZkzulC:www.visgen.com/Investors/Archived_Press_Releases/press3.shtml+p53+gene+skin+c)

Google is not affiliated with the authors of this page nor responsible for its content.

These search terms have been highlighted: **p53 gene skin cancer 1996**



HOME

COMPANY

NEWS, EVENTS &  
MEDIA

PRODUCTS & SERVICES

INVESTORS

RECENT PRESS RELEASES

ARCHIVED  
PRESS RELEASES

WEBCASTS

QUARTERLY REPORTS

ANNUAL REPORTS

STOCK QUOTES

INVESTOR CONTACTS

CAREERS

SITE MAP

CONTACT US

SEARCH



## INVESTORS

### Archived Press Releases

These pages are designed with investors in mind and include information on the company's performance.

**September 4, 1996**

Visible Genetics Inc.  
For Immediate Release

Contact:

For Visible Genetics Inc.

John K. Stevens, Chairman and C.E.O.

(416) 813-3242,

[john@visgen.com](mailto:john@visgen.com)

### VISIBLE GENETICS INC. RECEIVES U.S. PATENTS FOR P53 AND RB1 CANCER GENE TESTS

TORONTO, ONTARIO (September 4, 1996): Visible Genetics Inc. (VGI, VGINF) today announced the issuance of two U.S. patents covering the test kits that permit the rapid, inexpensive detection of mutations in two genes associated with human cancers. The first, U.S. Patent No. 5,545,527, covers the **p53 GeneKit**, which allows users to quickly and inexpensively detect p53 mutations in the DNA code of the **p53 gene**. The second, U.S. Patent No. 5,550,020, covers the **RB1 GeneKit**, which allows users to search for RB1 mutations in the **RB1 gene** from a simple blood sample.

Mutations in the **p53 gene** are found in a wide variety of tumors, including about 70% of colorectal cancers, 50% of lung cancers, and 40% of breast cancers. Moreover, aberrant forms of the **p53 gene** are reported to be associated with more aggressive tumors, metastasis and lower 5-year survival rates. Reports have emerged for cancers of the colon, lung, cervix, bladder, prostate and **skin**. Visible Genetics is developing its **p53 GeneKit** in collaboration with Eleftherios P. Diamandis, M.D. of the Mt. Sinai Hospital in Toronto. Diamandis comments, "The serious consequences of **p53 gene** mutations mandate a method of diagnosis that is rapid, accurate, and can be performed at the earliest stage of tumor development. There are literally millions of patients in North America who may benefit from use of this test."

RB1 mutations lead to retinoblastoma, a potentially curable eye cancer in children that is invariably fatal unless the tumor is destroyed at an early age by elimination by removal of the affected eye. Typically, children born to families that are repeatedly screened for the tumor using highly invasive methods costing thousands of dollars. A report by Brenda Gallie, M.D. of Toronto for Sick Children and the Eye Research Institute of Canada in the August issue of the American Journal of Human Genetics illustrates the potential for RB1 diagnostics to avoid trauma for infants and save health care dollars. That study shows that a savings of up to \$16,611 could be realized per child using DNA diagnostics to detect RB1 mutations instead of conventional





using DNA diagnostics to detect RB1 mutations instead of conventional of retinoblastoma diagnosis. Dr. Gallie is currently collaborating with Visible Genetics on the development of the RB1 GeneKit.

Both the RB1 and p53 GeneKits apply the Stratified Matrix methodology, the subject of U.S. Patent 5,545,527, also recently issued to Visible Genetics. This technology represents a fundamental departure from the conventional manner in which individual assays for genetic mutations have been performed as separate tests. Many individual assays may have low accuracy alone, but combined in a Stratified Matrix can produce a highly reliable and accurate diagnostic test with a significant reduction in the testing cost per patient.

John Stevens, Chairman and Chief Executive Officer of Visible Genetics, stated: "The RB1 and p53 GeneKits illustrate the value of Stratified Matrix as a new technology for the development of a variety of clinical DNA diagnostics."

Visible Genetics, Inc. develops, manufactures and markets high performance automated diagnostic DNA sequencing systems for genes linked to disease. The company's OpenGene™ system employs stratified DNA testing to significantly reduce the time and cost involved in finding and identifying disease-causing genetic mutations.

Your use of this page is subject to the terms and conditions of use that you agreed to be bound by in accessing the Visible Genetics Inc. website.

[Legal Statement](#)

This is Google's cache of <http://www.infobiogen.fr/services/chromcancer/Genes/P53ID88.html>.

Google's cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. Click here for the [current page](#) without highlighting.

To link to or bookmark this page, use the following url:

<http://www.google.com/search?q=cache:eySvjR5VLZUC:www.infobiogen.fr/services/chromcancer/Genes/P53ID88.html+p53+gene+skin+cancer>

*Google is not affiliated with the authors of this page nor responsible for its content.*

These search terms have been highlighted: **p53 gene skin cancer**

## Atlas of Genetics and Cytogenetics in Oncology and Haematology

[Home](#) [Genes](#) [Leukemias](#) [Solid Tumours](#) **[Cancer-Prone](#)** [Deep Insight](#) [Portal](#) [Teaching](#)

[X](#) [Y](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [21](#) [22](#) [NA](#)

### **P53 (Protein 53 kDa)**

#### **Identity**

Other names **TP53 (Tumour Protein 53)**

Hugo TP53

Location 17p13

#### **DNA/RNA**

Description the **gene** encompasses 20 kb of DNA; 11 exons (the first is non-coding).

Transcription 3.0 kb mRNA; 1179 bp open reading frame.

#### **Protein**

Description	393 amino acids ; 53 kDa protein ; numerous post translational modifications, phosphorylation, acetylation, ubiquitination; contains from N-term to C-term, a transactivation domain ((1-42), a Proline rich domain (63-97), a specific DNA binding domain (102-292), 3 nuclear localization signals (305-322), a tetramerization domain that include a nuclear export signal (325-355) and a negative regulatory domain (360-393)
Expression	widely expressed.
Localisation	nucleus.
Homology	the five domains are highly-conserved regions between species (from human to fly). Two new genes homologous to <b>p53</b> have been discovered, p73 localized at 1p36 and p63 localized at 3q27.

## Mutations

Germinal	in Li-Fraumeni syndrome, a dominantly inherited disease in which affected individuals are predisposed to develop sarcomas, osteosarcomas, leukemias and breast cancers at unusually early ages.
Somatic	<b>P53</b> is mutated in about 50% of human cancers, and the non-mutated allele is generally lost; the frequency and the type of mutation may vary from one tumour type to another; these mutations are missense (80%), non-sense (7.5%), deletions, insertions or splicing mutations (12.5%) ; there are some hot-spots for mutations at CpG dinucleotides at positions 175, 248, 273 and 282; <b>P53</b> mutation is an adverse prognostic feature in a number of <b>cancer</b> , but not in all. Mutational events are related to carcinogen exposure in lung, liver and <b>skin cancer</b> .

## Implicated in

Entity	<u>Li-Fraumeni syndrome</u>
Disease	autosomal dominant condition; <b>cancer</b> prone disease; Li-Fraumeni syndrome is defined by the existence of both a proband with a sarcoma and two other first-degree relatives with a <b>cancer</b> by age 45 years; a germline mutation of <b>P53</b> is found in at least 50% of cases; germline mutation of the kinase CHK2, an activator of <b>p53</b> , has been discovered in several Li-Fraumeni families free of <b>p53</b> mutation.
Prognosis	most common <b>cancer</b> in Li-Fraumeni children are : soft tissues sarcoma before the age of 5 yrs and osteosarcoma afterwards, and <b>breast cancer</b> in young adults; other frequent cancers: brain tumours, leukaemias, adrenocortical carcinoma; 1/3 of patients have developped more than one primary <b>cancer</b> , which is quite characteristic of Li-Fraumeni syndrome but may also be representative of <u>Bloom's syndrome</u> ; cancers in this disease, as in other <b>cancer</b> -prone diseases, often occur early in life: 50% of patients aged 30 yrs have had a <b>cancer</b> (i.e. penetrance is 50%, according to this disease definition); and penetrance is 90% at age 60 yrs.
Oncogenesis	(known) germinal mutation are variable, but are mostly missense mutations located in exons 4 to 9 in tumours occurring in these patients, the other (wildtype) allele is lost, in accordance with the two-hit model for neoplasia, as is found in retinoblastoma.

**Entity** haematological malignancies

**Oncogenesis** **P53 gene** alterations have been found in : 20 - 30% of blast crisis CML (mostly in the myeloid type), often associated with i(17q); in 5% of MDS cases and 15% of ANLL often with a visible del(17p); in 2% of ALL (but with high variations according to the ALL type, reaching 50% of L3 ALL (and Burkitt lymphomas); in 15% of CLL (and 40% in the aggressive CLL transformation into the Richter's syndrome) and 30% of adult T-cell leukaemia (only found in the aggressive form), in 5-10% of multiple myelomas; in 60-80% of Hodgkin disease; in 30% of high grade B-cell NHL (rare in low grade NHL), and 50% of HIV-related NHL; **P53 gene** alterations in haematological malignancies are associated with a poor prognosis.

**Entity** lung cancers

**Disease** lung cancers are neuroendocrine lung tumours (small cell lung carcinomas, carcinoids, large cell neuroendocrine carcinomas) or non neuroendocrine lung tumours (squamous carcinomas, adenocarcinomas, large cell carcinomas).

**Oncogenesis** is multistep, through **C-MYC** or **N-MYC** activation, **H-RAS1** or **K-RAS2** mutation, **P53**, **RB1**, and P16 inactivation, loss of heterozygosity (LOH) at 3p, 13q, 17p; P 53 mutations, in this particular case, does not seem to have prognostic implication; **P53** is mutated in 30% of lung adenocarcinomas to 80% of small cell lung carcinomas; hotspots at codons 157, 158, 179, 245, 248 and 273. **p53** mutations in lung **cancer** from smoker have a very specific pattern related to carcinogen exposure (high frequency to GC->TA transversion and hot spot at codon 157 and 158).

**Entity** colorectal cancers

**Disease** there are two types of colorectal cancers, according to the ploidy: - the diploid form, RER+ (Replication Error+), sporadic, without loss of heterozygosity (LOH), with few mutations of **p53** and APC, and right-sided; -the polyploid form, RER-, with LOH (5q, 17p, 18q), mutations in **p53**, and more often left-sided, they have a worse prognosis.

**Prognosis** survival, although improving, is not much more than 50% after 5 years

**Cytogenetics** diploid tumours without frequent allelic losses; aneuploid tumours with numerous allelic losses; LOH on chromosomes 17 and 18 in more than 75% of cases; other chromosome arms losses in about 50% of cases.

**Oncogenesis** a number of genes are known to be implicated in tumour progression in colorectal cancers : **APC**, **P53**, **KRAS2**, mismatch repair genes (MMR genes); **P53** is mutated in 60-65% of colorectal **cancer** cases; mutations of **P53** are mostly located in exons 4 to 8 with hotspots at codons 175, 245, 248, 273 and 282

**Entity** bladder **cancer**

**Prognosis** highly variable, according to the stage and the grade

**Cytogenetics** -9, -11 or del(11p), del(17p) and LOH at 17p, del(13q), frequent other LOH, aneuploidy, polyploidy, complex karyotypes.

**Oncogenesis** multi-step and largely unknown process; loss of 9q and **P53** mutations would be early events; **RB1**, and P16 inactivation, EGFR overexpression, LOH at 3p, 8p, 11p, 13q,

17p, 18q; **P53** is mutated in 40-60% of bladder **cancer** cases; P 53 mutations bear a prognostic implication.

**Entity** **breast cancer**  
**Prognosis** **P53** mutation bears a prognostic implication in N+ patients and is related to poor response to doxorubicin therapy.  
**Oncogenesis** **P53** is mutated in 30% of breast cancers; preferentially observed in advanced and aggressive forms; probably a late event; hotspots at codons 175, 248, and 273. The frequency and pattern of **p53** mutation in breast **cancer** is subject to important geographical variations.

**Entity** **skin cancers**  
**Disease** **skin** cancers include basal cell carcinomas, squamous cell carcinomas, and melanomas.  
**Prognosis** highly different according to the pathological group  
**Oncogenesis** **P53** is mutated in 40-60% of **skin** cancers; hotspots at codons 196, 248, 278. The pattern of **p53** mutation in **skin cancer** is highly related to UV exposure.

**Entity** oesophagus cancers  
**Disease** two main forms: squamous cell carcinoma and adenocarcinoma  
**Oncogenesis** **P53** is mutated in 50% of oesophagus cancers (70% in squamous cell carcinoma and 45% of adenocarcinoma); probably an early event; hotspots at codons 175, 248 and 273. The pattern of **p53** mutation is different in squamous cell carcinoma and adenocarcinoma

**Entity** **liver cancer**  
**Cytogenetics** losses of 1p, 4q, 5p, 5q, 8q, 13q, 16p, 16q, and 17p in 20 to 50% of cases  
**Oncogenesis** specific mutation at codon 249 related to aflatoxin B1 dietary exposure in exposed area (China, Africa); low frequency of mutation in developed countries.

**Entity** prostate **cancer** and other cancers (in progress)

### To be noted

germinal mutations of **P53** have also been found in families where the criteria for the Li-Fraumeni syndrome were not reached.

### External links

<a href="#">Hugo</a>	<a href="#">TP53</a>	<a href="#">Genes Cyto</a>	<a href="#">Gene Seq</a> [Map View - NCBI]
<a href="#">GeneCards</a>	<a href="#">TP53</a>		
<a href="#">CancerGene</a>	<a href="#">TP53</a>		
<a href="#">GDB</a>	<a href="#">TP53</a>		
<a href="#">Genatlas</a>	<a href="#">TP53</a>		
<a href="#">LocusLink</a>	<a href="#">TP53</a>	<a href="#">AceView</a> - NCBI	
<a href="#">GoldenPath</a>	<a href="#">TP53</a> - 17p13		
<a href="#">Ensembl</a>	<a href="#">TP53</a> - 17p13		
<a href="#">GeneLynx</a>	<a href="#">TP53</a>		
<a href="#">eGenome</a>	<a href="#">TP53</a>		
<a href="#">euGene</a>	<a href="#">7157</a>		
<a href="#">HomoloGene</a>	<a href="#">TP53</a>		
<a href="#">Genbank</a>	<a href="#">M14695</a> [SRS]	<a href="#">M14695</a> [ENTREZ]	
<a href="#">RefSeq</a>	<a href="#">M_000546</a> [SRS]	<a href="#">M_000546</a> [ENTREZ]	
<a href="#">RefSeq</a>	<a href="#">NT_010687</a> [SRS]	<a href="#">NT_010687</a> [ENTREZ]	
<a href="#">Unigene</a>	<a href="#">Hs.1846</a> [SRS]	<a href="#">Hs.1846</a> [NCBI]	<a href="#">HS1846</a> [spliceNest]
<a href="#">SwissProt</a>	<a href="#">P04637</a> [SRS]	<a href="#">P04637</a> [EXPASY]	<a href="#">P04637</a> [INTERPRO]
<a href="#">PDB</a>	<a href="#">1A1U</a> [SRS]	<a href="#">1A1U</a> [PdbSum]	<a href="#">1A1U</a> [IMB]
<a href="#">Pfam</a>	<a href="#">PF00870</a> [SRS]	<a href="#">PF00870</a> [Sanger]	<a href="#">pfam00870</a> [NCBI-CDD]
<a href="#">DOMO</a>	<a href="#">P04637</a>		
<a href="#">PRODOM</a>	<a href="#">P04637</a> [Domain structure]	<a href="#">P04637</a> [sequences sharing at least 1 domain]	
<a href="#">BLOCKS</a>	<a href="#">P04637</a>		
<a href="#">Human PSD</a>	<a href="#">TP53</a>		
<a href="#">PubGene</a>	<a href="#">TP53</a>		
<a href="#">OMIM</a>	<a href="#">191170</a>		
<a href="#">SNP</a>	<a href="#">TP53</a> [dbSNP-NCBI]		
<a href="#">SNP</a>	<a href="#">M_000546</a> [SNP-NCI]	<a href="#">NT_010687</a> [SNP-NCI]	
<a href="#">SNP</a>	<a href="#">TP53</a> [GeneSNPs - Utah]	<a href="#">TP53</a> [SNP - CSHL]	<a href="#">TP53</a> [HGBASE - SRS]
<a href="#">HGMD</a>	<a href="#">120445</a>		
Other database	<a href="#">The P53 Database</a>		
Other database	<a href="#">HotMolecBase</a>		
<a href="#">Probe</a>	<a href="#">P53</a> (17p13.1) in normal cells (Bari)		
<a href="#">Probe</a>	<a href="#">TP53 Related clones</a> (RZPD - Berlin)		

## Full Bibliography



**p53, the cellular gatekeeper for growth and division.**

Levine AJ.

Cell 1997; 88: 323-331.

Medline [9039259](#)**Li-Fraumeni syndrome - A molecular and clinical review.**

Varley JM, Evans DGR, Birch JM.

Brit J **Cancer** 1997; 76: 1-14.Medline [9218725](#)**The P53 pathway.**

Prives C, Hall PA.

J Pathol 1999; 187: 112-126.

Medline [10341712](#)**Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.**

Ljungman M.

Neoplasia 2000; 2: 208-225.

Medline [10935507](#)**Surfing the p53 network.**

Vogelstein B, Lane D, Levine AJ.

Nature 2000; 408: 307-310.

Medline [11099028](#)**Death star.**Vousden KH. **p53**.

Cell 2000; 103: 691-694.

Medline [11114324](#)**p63 and p73: p53 mimics, menaces and more.**

Yang A, McKeon F.

Nature Cell Biology 2000; 1: 199-207.

Medline [11252895](#)**Assessing TP53 status in human tumours to evaluate clinical outcome.**

Soussi T, Bérout C.

Nature **Cancer** Review 2001; 1: 233-240.**The evolution of diverse biological responses to DNA damage: insights from yeast and p53.**

Wahl, GM, Carr AM.

Nat Cell Biol 2001; 3: 277-286.

Medline [11781586](#)

**REVIEW articles - automatic search in PubMed****Last year publications - automatic search in PubMed****CancerGene Bibliographic Citations****Contributor(s)**

**Written**      07-1998    Richard Hamelin and Jean-Loup Huret  
**Updated**    10-1998    Richard Hamelin and Jean-Loup Huret  
**Updated**    12-2001    Thierry Soussi

**Citation**

*This paper should be referenced as such :*

**Hamelin R, Huret JL . P53** (Protein 53 kDa). Atlas Genet Cytogenet Oncol Haematol. July 1998 .  
URL : <http://www.infobiogen.fr/services/chromcancer/Genes/P53ID88.html>

**Hamelin R , Huret JL . P53** (Protein 53 kDa). Atlas Genet Cytogenet Oncol Haematol. October 1998

URL : <http://www.infobiogen.fr/services/chromcancer/Genes/P53ID88.html>

**Soussi T . P53** (Protein 53 kDa). Atlas Genet Cytogenet Oncol Haematol. December 2001 .  
URL : <http://www.infobiogen.fr/services/chromcancer/Genes/P53ID88.html>

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

indexed on : Fri Aug 9 16:01:32 MET DST 2002

---

**[Home](#) [Genes](#) [Leukemias](#) [Solid Tumours](#) [Cancer-Prone](#) [Deep Insight](#) [Portal](#) [Teaching](#)**

---

**For comments and suggestions or contributions, please contact us**  
**[j.l.huret@chu-poitiers.fr](mailto:j.l.huret@chu-poitiers.fr)**

---

This is Google's cache of <http://www.science.org.au/nova/008/008box03.htm>.

Google's cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. Click here for the [current page](#) without highlighting.

To link to or bookmark this page, use the following url:

<http://www.google.com/search?q=cache:eabxbiafndYC:www.science.org.au/nova/008/008box03.htm+p53+gene+skin+cancer&hl=en&ie=UTF-8>

Google is not affiliated with the authors of this page nor responsible for its content.

These search terms have been highlighted: **p53 gene skin cancer**



Sun and **skin** – a dangerous combination

### 3. The molecular mechanisms of **skin cancer**

Published by



Sponsored by



[Printer-friendly version of complete topic](#)

The body kills **skin** cells that have been exposed to too much ultraviolet radiation. Bringing about cell death is the function of a protein called **p53**. When an ultraviolet ray hits the DNA within a **gene** that codes for **p53**, basal cell and squamous cell **cancer** can result.

When present in a high enough concentration, the **p53** protein causes a cell to 'self-destruct'. This protein is normally produced in greater amounts after exposure to ultraviolet radiation. But after the radiation damages the **gene** for **p53**, the **p53** protein that the **gene** makes is slightly altered and doesn't function correctly. The defective version of the protein cannot make a damaged cell die.

The **gene** for **p53** only needs a very small change for a defective protein to be produced. This tiny error will be perpetuated whenever the cell divides. Eventually, many cells with the incorrect **gene** will exist.

The cells with the incorrect **gene** won't die when exposed to too much ultraviolet radiation. Instead they will reproduce, stimulated to do so because they find the normal cells around them dead. With each subsequent heavy exposure to too much sunlight, more normal cells will commit suicide, and the colony of cells with the damaged **gene** will multiply all the more. This is the beginning of a tumour.

So, by inducing cells carrying the normal **p53 gene** to kill themselves off, sunlight favours the proliferation of **p53-mutated** cells. Ultraviolet radiation is thus responsible for the two key steps in **cancer** generation: mutation and tumour promotion. The **p53 gene** and its protein are involved in the

KEY TEXT

GLOSSARY

ACTIVITIES

FURTHER READING

USEFUL SITES

development of basal cell carcinoma and squamous cell carcinoma, but not melanoma. A similar **gene**, p16, and its protein are thought to be involved in the development of melanoma, but these studies are preliminary.

### Further reading

- *Scientific American*, Vol. 275, no. 1, July 1996, pages 38-43  
*Sunlight and skin cancer* (by David J. Leffell and Douglas E. Brash)

### Related site

- **DNA and genes** (*Back to basics*, Australian Academy of Science)

---

External sites are not endorsed by the Australian Academy of Science.

---

Posted March 1997.



---

Telstra Corporation Ltd is the principal sponsor of *Nova: Science in the news*. The Australian Foundation for Science and the Federal Government's National Innovation Awareness Strategy are also supporters of *Nova*.

---

This topic is sponsored by Healthpact.

---

© Australian Academy of Science

---

This is Google's cache of <http://ehpnet1.niehs.nih.gov/docs/1996/Suppl-3/harris.html>.

Google's cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. Click here for the [current page](#) without highlighting.

To link to or bookmark this page, use the following url:

<http://www.google.com/search?q=cache:J8AneUa2EUC:ehpnet1.niehs.nih.gov/docs/1996/Suppl-3/harris.html+p53+gene+skin+cancer&hl=en&lc=UTP-8>

*Google is not affiliated with the authors of this page nor responsible for its content.*

These search terms have been highlighted: **p53 gene skin cancer**

Environmental Mutagens

Environmental Health Perspectives 104, Supplement 3, May 1996

[\[Citation in PubMed\]](#) [\[Related Articles\]](#)

## **p53 Tumor Suppressor Gene: At the Crossroads of Molecular Carcinogenesis, Molecular Epidemiology, and Cancer Risk Assessment**

**Curtis C. Harris**

Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, Maryland

### **Abstract**

Carcinogenesis is a multistage process involving the inappropriate activation of normal cellular genes to become oncogenes, e.g., *ras*, and the inactivation of other cellular genes called tumor suppressor genes. **p53** is the prototypic tumor suppressor gene that is well suited as a molecular link between the causes of cancer, i.e., carcinogenic chemical and physical agents and certain viruses, and the development of clinical cancer. The **p53** tumor suppressor gene is mutated in the majority of human cancers. Genetic analysis of human cancer is providing clues to the etiology of these diverse tumors and to the functions of the **p53** gene. Some of the mutations in the **p53** gene reflect endogenous causes of cancer, whereas others are characteristic of carcinogens found in our environment. In geographic areas where hepatitis B virus and a dietary chemical carcinogen, aflatoxin B<sub>1</sub>, are risk factors of liver cancer, a molecular signature of the chemical carcinogen is found in the mutated **p53** gene. A different molecular signature in the **p53** gene is found in skin cancer caused by sunlight. Because mutations in the **p53** gene can occur in precancerous lesions in the lung, breast, esophagus, and colon, molecular analysis of the **p53** gene in exfoliated cells found in either body fluids or tissue biopsies may identify individuals at increased cancer risk. **p53** mutations in tumors generally indicate a poorer prognosis. In summary, the recent history of **p53** investigations is a paradigm in cancer research, illustrating both the convergence of previously parallel lines of basic, clinical, and epidemiologic investigation and the rapid translation of research findings from the laboratory to the clinic. -- *Environ Health Perspect* 104(Suppl 3):435-439 (1996)

**Key words:** **p53** gene, molecular carcinogenesis, molecular epidemiology, cancer risk assessment

This paper was presented at the 2nd International Conference on Environmental Mutagens in Human Populations held 20-25 August 1995 in Prague, Czech Republic. Manuscript received 22 November 1995; manuscript accepted 28 November 1995.

The editorial and graphic assistance of Dorothea Dudek is appreciated.

Address correspondence to Dr. Curtis C. Harris, Laboratory of Human Carcinogenesis, National **Cancer** Institute, National Institutes of Health, Bldg. 37, Rm. 2C01, Bethesda, MD 20892-4255. Telephone: (301) 496-2048. Fax: (301) 496-0497. E-mail: [harris@dc37a.nci.nih.gov](mailto:harris@dc37a.nci.nih.gov)

---

[\[Table of Contents\]](#) [\[Full Article\]](#) [\[Citation in PubMed\]](#) [\[Related Articles\]](#)

Last Update: August 3, 1998